Gilead Sciences : Phase 3 Data Shows 96% Reduction In HIV Infections With Lenacapavir
8/10 03:25
(RTTNews) - Gilead Sciences Inc. (GILD) announced that additional data from its pivotal Phase 3 PURPOSE 2 trial demonstrated a 96% reduction in HIV infections with Lenacapavir compared to the background HIV incidence among a geographically diverse population of cisgender men and...